| 2.39 Data as of May 22 |  +0.01 / +0.42%Today’s Change | 1.97 Today|||52-Week Range 8.72 | +2.58% Year-to-Date |
| Previous close | 2.38 |
| Today’s open | 2.37 |
| Day’s range | -- - -- |
| Volume | 237,180 |
| Average volume (3 months) | 505,530 |
| Market cap | $149.5M |
| Dividend yield | -- |
| Earnings growth (last year) | +82.01% |
| Earnings growth (this year) | +51.22% |
| Earnings growth (next 5 years) | +20.00% |
| Revenue growth (last year) | +183.41% |
| P/E ratio | NM |
| Price/Sales | 4.61 |
| Price/Book | 1.39 |
| Today’s change | Today’s % change | |
|---|---|---|
| ZIOPZIOPHARM Oncology In... | -0.08 | -4.47% |
| TGTXTG Therapeutics Inc | -0.17 | -3.01% |
| AVEOAveo Pharmaceuticals... | -0.24 | -8.28% |
| POZNPOZEN Inc | -0.06 | -1.21% |
| Next reporting date | August 9, 2013 |
| EPS forecast (this quarter) | -$0.35 |
| Annual revenue (last year) | $19.6M |
| Annual profit (last year) | -$87.8M |
| Net profit margin | -447.20% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chairman, President & Chief Executive Officer Timothy P. Walbert |
Senior VP-Clinical Development & Operations Amy Grahn |
Corporate headquarters Deerfield, Illinois |
.
